Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

2.610 +0.160 (+6.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial
Alzamend Neuro Inc (NASDAQ: ALZN) announced it had completed the clinical portion of its Phase 2A multiple ascending dose (MAD) study of AL001 in subjects with dementia related to Alzheimer’s. 
Via Benzinga
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
From Alzamend Neuro, Inc.
Via Business Wire
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday. 
Via Benzinga
Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial
 
Via Benzinga
Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Alzamend Neuro to Present at Sequire Biotechnology Conference
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia
Alzamend Neuro Inc (NASDAQ: ALZN) has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
SEC Goes After 'MrZackMorris, 'Stock Sniper' For Alleged Fraud
Eight people connected to Atlas Trading, a Discord-based community, have been named in a complaint filed by the Securities and Exchange Commission (SEC). Co-founders of the forum, podcasters, and... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Friday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
From Alzamend Neuro, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday! 
Via InvestorPlace
5.6 Million Bet On This Penny Stock? Check Out These 3 Penny Stocks Insiders Are Buying
The Nasdaq Composite closed lower by around 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
WaveDancer And 1 Other Stock Under $2 Insiders Are Aggressively Buying
The Dow Jones dropped by more than 600 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
From Alzamend Neuro, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another overview of the biggest pre-market stock movers for Wednesday as we cover the news behind share movement this morning! 
Via InvestorPlace
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
 
Via Benzinga
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028. 
Via Benzinga
Alzamend Neuro Stock Pops After Benzinga Exclusive On Cognition Therapeutics Alzheimer's Data
Shares of biopharmaceutical company Alzamend Neuro Inc (NASDAQ: ALZN) are soaring Thursday afternoon after Cognition Therapeutics Inc (NASDAQ: CGTX) shares surged following the presentation of a... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.